Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cytek Biosciences
AddedFeb 19, 2024
UpdatedJun 18, 2026
Cytek Biosciences

Cytek Biosciences

Public

Biotech firm specializing in the production of scientific instruments.

HQ
Fremont, CA, US
Founded
2014
Overview
Compare
Fundraising
Employees
Website

Cytek Biosciences is a biotechnology company dedicated to advancing cell analysis through innovative scientific instruments. Their core mission is to unlock new dimensions in cellular analysis by integrating advanced technologies such as AI with high-quality imaging. Key products include the Cytek Amnis® AI v3 image analysis software and the Cytek Aurora™ CS system, which has been recognized as the "Cell Sorting Product of the Year" by BioTech Breakthrough. Cytek focuses on providing cutting-edge solutions for researchers and clinicians in the life sciences market.

Cytek Biosciences has made significant strides in the biotechnology field, particularly with their Aurora™ CS system, which has garnered industry accolades for its advanced cell sorting capabilities. Their integration of AI in the Amnis® imaging flow cytometer has set new standards in cellular analysis, enhancing research accuracy and efficiency. These achievements underscore Cytek's impact on scientific research and its commitment to innovation in biotechnology.

Cytek Biosciences - Quick Facts

When was Cytek Biosciences founded?

Cytek Biosciences was founded in 2014.

Where is Cytek Biosciences' headquarters located?

Cytek Biosciences' headquarters is located in Fremont, CA, US.

How much has Cytek Biosciences raised to-date?

As of Jan 1, 2021, Cytek Biosciences has raised a total of $144.3M (USD).

How many employees does Cytek Biosciences have?

Cytek Biosciences has 583 employees as of Feb 6, 2024.

Cytek Biosciences - Classification

Industry
  • Hardware
Ownership
  • Public
Technology
  • AI
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Scientific Instruments
Tags
  • Data
  • Research
Unique IDs
  • ein: 472547526
  • secCik: 0001831915
  • ticker: CTKB
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 3820Laboratory Apparatus And Analytical, Optical, Measuring, And Control
  • 3826Laboratory Analytical Instruments
ISIC
  • 2651Manufacture of measuring, testing, navigating and control equipment
Show 14 more industry codes
NAICS
  • 334500Navigational, Measuring, Electromedical, and Control Instruments Manufacturing
  • 334510Navigational, Measuring, Electromedical, and Control Instruments Manufacturing
  • 334516Analytical Laboratory Instrument Manufacturing
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 334000Computer and Electronic Product Manufacturing
  • 623000Nursing and Residential Care Facilities
SIC
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research